Nuvectis director awarded 35,000 restricted shares

Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.

Nuvectis Pharma, Inc. director Kenneth Hoberman received a grant of 35,000 shares of restricted common stock. The award was granted at no cash cost per share and is a form of equity compensation rather than an open-market purchase.

The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Hoberman continues serving on the company’s Board of Directors. After this grant, he directly holds 168,140 shares of common stock, which includes restricted shares.

Insider Trade Summary

Grant/Award: 35,000 shares

Grant/Award 1 txn

Insider Hoberman Kenneth

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	35,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 168,140 shares (Direct)

Footnotes (2)

1. F1. The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates.
2. F2. Includes shares of restricted common stock.

Key Figures

Restricted stock grant: 35,000 shares Grant price per share: $0.0000 per share Total holdings after grant: 168,140 shares +1 more

4 metrics

Restricted stock grant 35,000 shares Equity award of common stock

Grant price per share $0.0000 per share Reported transaction price

Total holdings after grant 168,140 shares Common stock directly owned post-transaction

Vesting period 3 years Equal annual installments from first anniversary

Key Terms

restricted common stock, vest, grant date

3 terms

restricted common stock financial

"The 35,000 shares of restricted common stock will vest in equal annual installments over three years"

Restricted common stock is company shares that carry limits on selling or transferring for a set period or until certain conditions are met, like time-based vesting or regulatory clearance. Think of them as shares in a locked box that gradually open; they can become freely tradable later but initially reduce the number of shares available on the market. Investors watch restricted stock because its eventual release can change a company’s share supply, affect stock price, and influence control and dilution.

vest financial

"will vest in equal annual installments over three years beginning on the first anniversary of the grant date"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant date financial

"beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nuvectis Pharma (NVCT) director Kenneth Hoberman report in this Form 4?

Kenneth Hoberman reported receiving 35,000 shares of restricted common stock as an equity grant. The award was issued at no cash cost per share and increased his direct holdings to 168,140 shares of Nuvectis Pharma common stock, including restricted shares.

Is Kenneth Hoberman buying or selling Nuvectis Pharma (NVCT) stock in this filing?

This filing shows an acquisition through an equity grant, not a market trade. Hoberman received 35,000 restricted shares as compensation, coded as a grant or award, with no open-market buying or selling activity disclosed in this Form 4 transaction.

How do the 35,000 restricted Nuvectis Pharma (NVCT) shares vest for Kenneth Hoberman?

The 35,000 restricted shares vest in three equal annual installments. Vesting begins on the first anniversary of the grant date, and each installment requires Hoberman’s continued service on Nuvectis Pharma’s Board of Directors on the applicable vesting dates.

What are Kenneth Hoberman’s total Nuvectis Pharma (NVCT) holdings after this grant?

After the grant, Hoberman directly holds 168,140 shares of Nuvectis Pharma common stock. This total includes the newly granted restricted shares and other restricted common stock already held, as indicated in the Form 4 footnote disclosure.

Does this Nuvectis Pharma (NVCT) Form 4 indicate any derivative or option exercises?

The Form 4 reflects only a non-derivative equity grant of common stock. It reports no derivative securities, option exercises, or other derivative transactions, and the derivative holdings section in the provided data is empty for this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:12 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoberman Kenneth

(Last) (First) (Middle)

C/O NUVECTIS PHARMA, INC.,

1 BRIDGE PLAZA, SUITE 275

(Street)

FORT LEE NEW JERSEY 07024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nuvectis Pharma, Inc. [ NVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		A		35,000(1)	A	$0	168,140(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates.

2. Includes shares of restricted common stock.

	/s/ Kenneth Hoberman	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)